Black Friday saleUp to 70% OFF

Pharmaceutical

Is Pfizer's Golden Goose About to Lay a Different Egg?Pfizer, the pharmaceutical giant that became a household name during the pandemic, now faces a pivotal moment. Activist investor Starboard Value has taken a $1 billion stake, signaling potential changes on the horizon. But what does this mean for Pfizer's future? The company that swiftly developed a COVID-19 vaccine now grapples with declining sales and a tumbling stock price. Starboard's involvement brings both challenge and opportunity. Will this be the catalyst for Pfizer's renaissance or a sign of deeper troubles ahead? Former Pfizer executives have been approached to assist in the turnaround effort. Their potential involvement adds an intriguing layer to this unfolding story. Could their experience and insight be the key to unlocking Pfizer's next chapter of success and innovation? As the pharmaceutical landscape evolves post-pandemic, Pfizer's response to this pressure could set industry trends. Cost-cutting, strategic refocusing and potential leadership changes loom large. How will these moves impact drug development, patient care, and the broader healthcare ecosystem? For investors, patients, and industry watchers, Pfizer's next moves are crucial. Will the company emerge stronger, leaner, and more innovative? Or will it struggle to find its footing in a rapidly changing market? The answers to these questions could reshape the future of global healthcare.
NYSE:PFELong
by signalmastermind
2
Eli Lilly's Zepbound: A Game-Changer for Obesity Treatment?In a groundbreaking move that could redefine the landscape of obesity treatment, Eli Lilly has slashed the price of its weight loss drug, Zepbound, by half. But is this simply a strategic business decision, or is it a beacon of hope for millions struggling with obesity? Join us as we delve into the implications of this bold move and explore the potential impact on the future of weight management. Imagine a world where obesity is no longer a daunting, insurmountable challenge. A world where effective, affordable treatments are accessible to all who need them. Eli Lilly's recent announcement of a significant price reduction for Zepbound brings us closer to that reality. By making this groundbreaking decision, Eli Lilly has not only demonstrated its commitment to patient access but has also sent a powerful message to the broader healthcare industry. This move has the potential to disrupt the status quo, challenging the outdated policies and practices that have hindered progress in obesity treatment. As we explore the implications of Eli Lilly's decision, we must consider the broader context of the obesity epidemic. For decades, obesity has been stigmatized and overlooked as a serious medical condition. Many individuals struggling with weight loss have faced limited treatment options and significant financial burdens. Eli Lilly's move to lower the price of Zepbound could be a game-changer in this regard. By making the drug more affordable, the company is empowering patients to take control of their health and pursue a healthier lifestyle. This could lead to a significant increase in the number of people seeking treatment for obesity, ultimately improving public health outcomes. However, it is important to note that this is just one step in a larger journey. While Eli Lilly's decision is undoubtedly a positive development, more needs to be done to address the systemic issues that contribute to the obesity epidemic. Policymakers, healthcare providers, and communities must work together to create a supportive environment that promotes healthy eating, physical activity, and access to affordable, effective treatments. In conclusion, Eli Lilly's announcement of a price reduction for Zepbound represents a significant milestone in the fight against obesity. By making this drug more accessible, the company is not only helping individuals achieve their weight loss goals but also challenging the broader healthcare system to prioritize obesity treatment.
NYSE:LLYLong
by signalmastermind
CVS - CVS Health: If the stock drops a few points, I'll be buyiIf the stock drops a few points, I'll be buying very heavily... CVS and WBA are in the same sector. And both have been decimated. CVS, however, is doing better. And they're paying a dividend. Target, at least +10%. Trading at 70% below estimate of its fair value Earnings are forecast to grow 9% per year Earnings grew by 140% over the past year DIVIDEND = Pays a high and reliable dividend of 4.75% Trading at good value compared to peers and industry Analysts in good agreement that stock price will rise by 20%
NYSE:CVSLong
by Maximus20000
Bayer AG (BAYN.de) bullish scenario:The technical figure Falling Wedge can be found in the daily chart in the German company Bayer AG (BAYN.de). Bayer AG is a German multinational pharmaceutical and biotechnology company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include pharmaceuticals; consumer healthcare products, agricultural chemicals, seeds and biotechnology products. The Falling Wedge broke through the resistance line on 22/03/2023. If the price holds above this level, you can have a possible bullish price movement with a forecast for the next 9 days towards 60.750 EUR. According to experts, your stop-loss order should be placed at 54.890 EUR if you decide to enter this position. Bayer AG plans to spend $1 billion on drug research and development in the U.S. this year as it works to double its sales in the country by the end of the decade, Bayer's top U.S. pharmaceutical executive told Reuters. Sebastian Guth, president of Bayer's pharmaceuticals business in the Americas, in an interview with Reuters, said the company increased U.S. employees working on marketing for its pharmaceutical business by around 50% over the last three years and plans to expand on that by another 75% by 2030. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals and cannot be held liable nor guarantee any profits or losses.
XETR:BAYNLong
by legacyFXofficial
FRTX | This Will Rocket! | 200%+ PotentialFresh Tracks Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was formerly known as Brickell Biotech, Inc. and changed its name to Fresh Tracks Therapeutics, Inc. in September 2022. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.
FLong
by DivergenceSeeker
Novartis (NOVN.vx) bullish scenario:The technical figure Double Bottom can be found in the Swiss company Novartis International AG (NOVN.vx) at daily chart. Novartis International AG is a Swiss multinational pharmaceutical corporation. It is one of the largest pharmaceutical companies in the world. Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), cyclosporine (Neoral/Sandimmune), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), deferasirox (Exjade), and others. The Double Bottom has broken through the resistance line on 07/04/2022, if the price holds above this level you can have a possible bullish price movement with a forecast for the next 29 days towards 86.88 CHF. Your stop-loss order according to experts should be placed at 72.50 CHF if you decide to enter this position. Novartis CEO Vas Narasimhan is continuing his shake-up of the giant Swiss drugmaker, announcing a corporate restructuring on Monday that the company says will simplify its organizational chart and bring more than $1 billion in annual savings. Novartis AG NVS announced that the FDA has approved its kinase inhibitor, Vijoice (alpelisib), for the treatment of patients aged two years and above with severe manifestations of PIK3CA-Related Overgrowth Spectrum (“PROS”), requiring systemic therapy. Per the company, following the nod, Vijoice became the first FDA-approved therapy to treat PROS, which includes rare conditions where overgrowths and blood vessel anomalies occur. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
SIX:NOVNLong
by legacyFXofficial
ObsEva, emerging company on verge of phase 3 completion Hi Ya'll, I hope you're having a Good Friday night. I came across this gem yesterday and I have to give it a shout out. ObsEva is a unique company, and has lots of potential. They have three drugs currently in pipelines. Its recently broken out and is channeling upward and moving very healthily. I have a price target of $10+. With a long term hold. Yselty- Phase 3 Ebopripant - Phase 2 Nolasiban -Phase 1 www.obseva.com Yselty is about to be finished testing. It looks positive and ready to be sold world wide. This product is very good for dealing with uterary fibroids which is very common and has no clear medication to use to solve it. If y'all can post your own understanding of the significance of these drugs I would appreciate it. I do not fully understand what these drugs do but they seem to be a big deal. Many analysts have set price targets ranging from $4.00-$28.00 a share. I will link this. www.tipranks.com Please give the company corporate presentation a look, and please tell me if I missed anything crucial, like the executives, etc.. www.obseva.com Thanks, Benjamin
OLong
by benarcotta
1
Vanda Pharmaceuticals! Earnings 40% Trade!!FA: Earings release- the last earnings where the estimate was higher than 0.05 per share it led to the stock rallying by 40%- unless, the earings surprise is a negative one; we can expect a rally from Vanda Pharmaceuticals. TA: Currently been trading in a limited channel- lack of momentum could lead to a dump if earnings estimate is negative or perhaps mean no rally even if the earnings estimate is positive. Watch out for the resistance, it is unlikely to take it out in these market conditions. -Megalodon Whales (Rahim) Enjoyed Charting this for you all,Please SHARE/LIKE/COMMENT and you are welcome to give your feedback or post your own charts below :) NASDAQ:VNDA FWB:VM4
NASDAQ:VNDALong
by BoSukas
2
Best Penny Stocks 🚀 to buy and watch in May 2020NASDAQ:EVFM 😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks FDA date of approval - 25th of May Our Strategy with this Stock : This company is a silent player in beer bug vaccination , I'm keeping an eye on it due to the strong upper trend of the company. I'm putting two alarms, one at 2.99 to monitor any anticipatory run up. I'm putting two alarms, one at 2.40 to monitor if it hit the support . What’s the real story : The beauty of Penny stock that I trade in particular , They are ALL pharmaceutical companies. The AMAZING part is 90% of Biotech penny stocks get approved , Still there is 10% that will go the other way ! That's why I'm here for my students to scan all the markets and give them the conclusion that I personally apply . How can you actually use this ? We ONLY trade regarding the news ! Meaning that when we see the anticipatory run UP I start trading it and letting my students and followers take the advantage 👨‍🎓. The Best Part You can follow me and apply my trades for FREE !!! QUESTIONS ? Please comment below , what you have in mind 😊
ELong
by UnknownUnicorn6877177
2
Golden Goose IPO "PPD" This IPO was just listed on FEB, 6th 2020 and will be killing it every earnings and has the potential to big a really big play in the market during these times. The chart I have posted is a 4HR time frame. Definitely one to add to your portfolio for awhile! I can see this being a GOLDEN GOOSE to get into early during these times! options plays are good on this one as well to play. Pivot points and resistance are $26.86 / $28 / $29.37 on the 4HR time frame. The Linear reg. channel is bullish on all time frames up to the 3 min. when it becomes semi neutral. Listed at 100% buy right now on Robinhood NASDAQ:PPD Inc. provides drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. The firm also provides clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations and other industry participants. Its clinical development services include all phases of development (Phase I-IV), peri- and post-approval and site and patient access services; laboratory services offers advanced testing services, including bioanalytical, biomarker, vaccine, good manufacturing practice and central laboratory services. The company was founded by Fred Eshelma in 1985 and is headquartered in Wilmington, NC.
PLong
by The_OnlyRule
Best Penny Stocks 🚀 to buy and watch in May 2020NASDAQ:AQST 😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks Our Strategy with this Stock : the company will release the drug for Parkinson disease treatment, The analysts are writing the stock at $17 to drive the sheep to buy the stock , while safe Traders will look for a high price of 6.18 $ . I'm putting two alarms, one at 4.79 to monitor any anticipatory run up. I'm putting two alarms, one at 3.37 to monitor if it hit the support . What’s the real story : The beauty of Penny stock that I trade in particular , They are ALL pharmaceutical companies. The AMAZING part is 90% of Biotech penny stocks get approved , Still there is 10% that will go the other way ! That's why I'm here for my students to scan all the markets and give them the conclusion that I personally apply . How can you actually use this ? We ONLY trade regarding the news ! Meaning that when we see the anticipatory run UP I start trading it and letting my students and followers take the advantage 👨‍🎓. The Best Part You can follow me and apply my trades for FREE !!! QUESTIONS ? Please comment below , what you have in mind 😊
NASDAQ:AQSTLong
by UnknownUnicorn6877177
3
Best Penny Stocks 🚀 to buy and watch in May 2020 NASDAQ:AYTU 😊Please LIKE & FOLLOW for more VIP Hunters signals , penny stocks Our Strategy with this Stock : This company specializes in UV light treatment and the previous history of this company how it strongly reacted with positive news and also negative news . I'm putting two alarms, one at 1.70 to monitor any anticipatory run up. I'm putting two alarms, one at 1.30 to monitor if it hit the support . What’s the real story : The beauty of Penny stock that I trade in particular , They are ALL pharmaceutical companies. The AMAZING part is 90% of Biotech penny stocks get approved , Still there is 10% that will go the other way ! That's why I'm here for my students to scan all the markets and give them the conclusion that I personally apply . How can you actually use this ? We ONLY trade regarding the news ! Meaning that when we see the anticipatory run UP I start trading it and letting my students and followers take the advantage 👨‍🎓. The Best Part You can follow me and apply my trades for FREE !!! QUESTIONS ? Please comment below , what you have in mind 😊
NASDAQ:AYTULong
by UnknownUnicorn6877177
2